Research

American Heart Association Omega-3 Recommendations in 2026 — What the Science Advisory Says

The American Heart Association has recommended omega-3-rich seafood as part of a heart-healthy dietary pattern for decades, but fish, over-the-counter fish oil, and prescription omega-3 medications are not the same recommendation. Current AHA public guidance emphasizes eating fish, particularly fatty fish, at least twice per week. A separate AHA science advisory covers prescription omega-3 medications for high triglycerides. The evidence base includes the AHA seafood omega-3 science advisory, the AHA hypertriglyceridemia advisory, and large cardiovascular outcome trials such as REDUCE-IT and ASCEND. Those sources are useful, but they should not be compressed into a single blanket fish-oil claim. For people searching 'American Heart Association fish oil recommendation 2025' or 'AHA omega-3 recommendations 2025/2026': the key distinction is dietary fatty fish first, careful interpretation of OTC omega-3 supplements, and prescription omega-3 only for specific medical contexts such as high triglycerides under clinician supervision. This page summarizes the AHA's evidence-based position, explains the dose distinctions, clarifies what the major trials showed, and links to our omega-3 for heart health page for readers who still want to evaluate EPA/DHA content, oxidation testing, and label quality.

Written by Editorial Team··Updated July 18, 2026

This content is for educational purposes only and is not medical advice. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

AHA Omega-3 Guidance At a Glance

The American Heart Association draws a hard line between diet, over-the-counter supplements, and prescription therapy. Here is the guidance compressed to four numbers:

AHA public guidance: eat 2 servings of fatty fish per week — this is the AHA's primary, broadly applicable, food-first recommendation.
Prescription omega-3 for high triglycerides: 3-4 g/day EPA+DHA under physician supervision, as an adjunct to diet and lifestyle for adults with hypertriglyceridemia — triglycerides at or above 200 mg/dL (500 mg/dL and above is classed 'very high').
REDUCE-IT prescription EPA (Vascepa): 4 g/day of purified EPA reduced major cardiovascular events by 25% in adults with elevated triglycerides plus established CVD or diabetes on statin therapy.
What the AHA does NOT recommend: standard over-the-counter fish oil as a blanket disease-prevention therapy for the general population — that jump is not supported by the evidence.

AHA vs EFSA vs NIH vs WHO: How Omega-3 Guidance Compares Worldwide

Readers searching for the AHA's omega-3 position are often trying to work out whether it lines up with what other major health authorities say, or whether it is a US-specific outlier. It largely agrees with the international consensus on a floor near 250 mg/day of combined EPA and DHA, but the four bodies differ sharply in how prescriptive they get about supplements, prescriptions, and specific populations. The table below compares the American Heart Association (AHA) against the European Food Safety Authority (EFSA), the U.S. National Institutes of Health Office of Dietary Supplements (NIH ODS), and the World Health Organization's joint consultation with the Food and Agriculture Organization (WHO/FAO).

Comparison point	American Heart Association	European Food Safety Authority	National Institutes of Health	World Health Organization
Recommended dose (general population)	2 servings of fatty fish per week (food-first guidance); 3-4 g/day EPA+DHA under physician supervision for hypertriglyceridemia (triglycerides ≥200 mg/dL; ≥500 = very high); 4 g/day pure EPA (Vascepa) for elevated triglycerides plus established CVD or diabetes.	250 mg/day combined EPA+DHA (Adequate Intake) for all healthy adults, plus an additional 100-200 mg/day DHA during pregnancy and lactation.	No EPA+DHA-specific target. The Adequate Intake covers total omega-3s as ALA only: 1.6 g/day for men and 1.1 g/day for women (ages 19+). The 2020-2025 Dietary Guidelines for Americans separately recommend at least 8 oz (about 2 servings) of seafood per week.	250 mg/day EPA+DHA as a floor for the general adult population, with an acceptable macronutrient distribution range up to 2 g/day, per the 2010 FAO/WHO joint expert consultation.
Target population	General population for diet-first guidance; prescription tiers reserved for adults with confirmed hypertriglyceridemia or established cardiovascular disease/diabetes on statin therapy.	General healthy adult population across EU member states, with separate incremental guidance for pregnant and lactating women.	General US population ages 19 and older; the fact sheet explicitly declines to set an EPA/DHA-specific population target.	General adult population worldwide; the underlying report notes the evidence is strongest for secondary prevention of coronary heart disease.
Dietary vs supplemental preference	Explicitly diet-first: fatty fish before OTC fish oil. OTC supplements are not treated as an AHA-endorsed prevention therapy; prescription is reserved for the highest-risk tier.	Source-neutral: the Adequate Intake can be met through diet, fortified foods, or supplements — EFSA does not rank diet above supplementation.	Diet-first framing ('nutritional needs should be met primarily through the diet'), but does not issue a specific supplemental EPA/DHA target to compare against.	Source-neutral numeric range; the underlying 2010 report references roughly two 90g portions of oily fish per week as one practical way to reach the lower bound.
Primary evidence base	AHA Science Advisories (Rimm et al. 2018, PMID 29773586) plus outcome trials REDUCE-IT (PMID 30415628) and ASCEND (PMID 30146932).	2010 EFSA NDA Panel Scientific Opinion on Dietary Reference Values for fats (EFSA Journal 2010;8(3):1461, DOI 10.2903/j.efsa.2010.1461).	2005 Institute of Medicine Dietary Reference Intakes for macronutrients, summarized in the NIH Office of Dietary Supplements omega-3 fatty acids fact sheet.	2010 FAO/WHO Joint Expert Consultation, 'Fats and Fatty Acids in Human Nutrition' (FAO Food and Nutrition Paper 91, PMID 21812367).
Key nuance	The only one of the four that explicitly separates food, OTC supplement, and prescription-drug guidance into distinct tiers with different evidence standards for each.	Sets a single numeric Adequate Intake without distinguishing OTC quality, prescription contexts, or disease-specific dosing the way the AHA does.	The only one of the four that declines to set any EPA/DHA-specific number at all — a deliberate evidence gap the fact sheet states directly, not an oversight.	Sets both a floor (250 mg/day) and an upper acceptable range (2 g/day), while noting in its own report that future trials could justify revising the ceiling.

Common Questions

Frequently Asked Questions

What does the AHA currently recommend for omega-3 intake in 2025-2026?

Current AHA public guidance emphasizes at least 2 servings of fish, particularly fatty fish, per week as part of a heart-healthy diet. Prescription omega-3 is a separate medical category used under clinician supervision for high triglycerides. OTC fish-oil supplements are not the same as prescription EPA/DHA products and should not be treated as a blanket AHA disease-prevention recommendation.

How much fish oil should I take per the AHA recommendation?

The AHA's public diet-first recommendation is to eat fish, especially fatty fish, at least twice per week. If you are considering OTC fish oil because you do not eat fish, review EPA+DHA content, oxidation testing, medication interactions, and your health context with a clinician. For high triglycerides, AHA guidance concerns prescription omega-3 products at medical doses under physician supervision, not ordinary OTC fish-oil capsules.

Is the AHA recommendation for fish oil or for fish in the diet?

The clearest AHA public recommendation is dietary: at least 2 servings of fish, particularly fatty fish, per week. OTC fish-oil supplements are a separate consumer category and are not equivalent to eating fish or to prescription omega-3 therapy.

Does the AHA recommend fish oil for everyone or only people with heart disease?

The AHA's dietary omega-3 recommendation, fatty fish twice per week, applies broadly as part of a heart-healthy diet. Prescription high-dose omega-3 is for specific medical contexts such as high triglycerides under physician supervision. OTC fish oil is not a universal AHA recommendation for everyone.

What happened with the REDUCE-IT trial and does it change the AHA recommendation?

REDUCE-IT (2019) showed that 4g/day of pure EPA (icosapentaenoic acid, as Vascepa) reduced major cardiovascular events by 25% in adults with elevated triglycerides and established CVD or diabetes on statin therapy. This is the strongest cardiovascular outcome evidence in the omega-3 category. However, REDUCE-IT used a pharmaceutical-grade, FDA-approved prescription drug (not OTC fish oil), pure EPA rather than EPA+DHA, and there is ongoing scientific debate about whether the mineral oil placebo used may have artificially raised CV events in the control arm. The AHA Advisory acknowledges REDUCE-IT's findings while noting these uncertainties. OTC fish oil at 1g/day is not equivalent to prescription Vascepa at 4g/day.

How should I evaluate omega-3 supplements if I do not eat fish?

Look for products that disclose EPA and DHA content separately, not just total fish oil. Third-party testing (IFOS, NSF, Informed Sport, or equivalent) is important for potency, freshness, oxidation, and heavy-metal checks. This is product-quality guidance, not a claim that OTC fish oil is equivalent to AHA-recommended dietary fish or prescription omega-3 therapy.

What triglyceride level qualifies for prescription omega-3?

Two different prescription thresholds come up in AHA-related guidance, and they are not interchangeable. For prescription-grade omega-3 preparations generally (3-4g/day EPA+DHA) as an adjunct to diet and lifestyle, the AHA hypertriglyceridemia advisory addresses adults with hypertriglyceridemia — triglycerides at or above 200 mg/dL (200-499 mg/dL is 'high' and 500 mg/dL or above is 'very high'). For prescription pure EPA (icosapentaenoic acid, Vascepa) specifically, the REDUCE-IT trial enrolled adults with triglycerides of 135-499 mg/dL who also had established cardiovascular disease or diabetes and were already on statin therapy. Neither threshold is a self-diagnosis tool — a clinician interprets your lipid panel and overall cardiovascular risk before recommending prescription omega-3.

Research Updates

Get healthy-aging evidence updates without the hype.

The free guide summarizes supplement evidence, quality signals, and safety questions in a practical checklist format.

Get the free guide

Primary Sources

Citations & Research

[1]Seafood Long-Chain n-3 Polyunsaturated Fatty Acids and Cardiovascular Disease: A Science Advisory From the American Heart AssociationSource
[2]Cardiovascular Risk Reduction with Icosapentaenoic Acid for HypertriglyceridemiaSource
[3]Effects of n-3 Fatty Acid Supplements in Diabetes MellitusSource
[4]Fats and fatty acids in human nutrition. Report of an expert consultationSource
[5]Scientific Opinion on Dietary Reference Values for fats, including saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, trans fatty acids, and cholesterolSource
[6]Omega-3 Fatty AcidsSource
[7]Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart AssociationSource